|
Volumn 98, Issue 12, 2001, Pages 6783-6788
|
CD3-mediated activation of tumor-reactive lymphocytes from patients with advanced cancer
|
Author keywords
Immunotherapy; Transforming growth factor type 1; Tumor immunity; Tumor vaccines
|
Indexed keywords
CD28 ANTIGEN;
CD3 ANTIGEN;
CD40 ANTIGEN;
GAMMA INTERFERON;
LYMPHOKINE;
MONOCLONAL ANTIBODY;
T LYMPHOCYTE RECEPTOR;
TRANSFORMING GROWTH FACTOR BETA1;
ADVANCED CANCER;
ANTIGEN EXPRESSION;
ANTIGEN PRESENTING CELL;
ARTICLE;
CLINICAL ARTICLE;
CONTROLLED STUDY;
CYTOKINE PRODUCTION;
CYTOKINE RELEASE;
CYTOTOXIC T LYMPHOCYTE;
HUMAN;
HUMAN CELL;
LYMPHOCYTE ACTIVATION;
LYMPHOCYTE PROLIFERATION;
PRIORITY JOURNAL;
SENSITIZATION;
T LYMPHOCYTE SUBPOPULATION;
TUMOR IMMUNITY;
ANTIBODIES, MONOCLONAL;
ANTIGENS, CD28;
ANTIGENS, CD3;
ANTIGENS, CD40;
COCULTURE TECHNIQUES;
HISTOCOMPATIBILITY ANTIGENS CLASS I;
HUMANS;
INTERFERON TYPE II;
LYMPHOCYTE ACTIVATION;
LYMPHOCYTES, TUMOR-INFILTRATING;
NEOPLASMS;
TRANSFORMING GROWTH FACTOR BETA;
TUMOR NECROSIS FACTOR-ALPHA;
|
EID: 0035811007
PISSN: 00278424
EISSN: None
Source Type: Journal
DOI: 10.1073/pnas.021557498 Document Type: Article |
Times cited : (34)
|
References (29)
|